Study released comparing travoprost and latanoprost

Article

Patients suffering from primary open-angle glaucoma (POAG) or ocular hypertension have been shown to respond better to travoprost than latanoprost according to a recent study.

Patients suffering from primary open-angle glaucoma (POAG) or ocular hypertension have been shown to respond better to travoprost than latanoprost according to data published in Clinical Ophthalmology.

The study by Dr Michael Miyashiro of Ludwig Ophthalmology Centre, Hilo, USA, et al. examined the efficacy, tolerability and safety of travoprost 0.004% BAK-free in 20 Japanese patients with POAG or ocular hypertension living in the US who had previously used latanoprost 0.005%. Each patient was transferred from latanoprost monotherapy to travoprost monotherapy for 12 weeks. They were all given the same series of tests to evaluate the efficacy, safety and tolerability of latanoprost during the initial visit and then of travoprost BAK-free during the final visit.

It was found that there was no significant difference in the patients' IOP levels, mean ocular hyperaemia, visual acuity, corneal fluoroscein staining or overall scores from the Ocular Surface Disease Index when using either therapy. However, it was noted that patients had a shorter mean tear break-up time on latanoprost. Additionally, more patients preferred the travoprost BAK-free monotherapy in comparison to latanoprost.

Based on the results it was suggested that the Japanese-American patients transitioned from latanoprost to travoprost BAK-free can expect to gain similar IOP control and some improvement in anterior segment signs with both treatments but the patient preference was towards travoprost at a ratio of 2:1.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.